Efficacy of Combining Prophylactic Curosurf With Early Nasal CPAP in Delivery Room: the Curpap Study
- Conditions
- Respiratory Distress Syndrome, Newborn
- Interventions
- Drug: Poractant alfa (Curosurf®)
- Registration Number
- NCT00501982
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Brief Summary
The primary objective of this study is to compare two methods of post-delivery stabilization and subsequent early respiratory care for reducing the need for MV and related secondary complications, such as BPD, in premature babies at high risk of RDS:
1. Early stabilization on nCPAP
2. Intubation, prophylactic surfactant (Curosurf®) administration shortly after delivery, and rapid extubation to nCPAP.
The data obtained from this comparison will be applied to test the hypothesis that preterm neonates at risk of RDS who are treated with prophylactic surfactant + nCPAP show less need for MV when compared to infants who receive nCPAP alone.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 208
- Preterm neonates with a gestational age (GA) of 25+0 - 28+6 completed weeks.
- Inborn neonates.
- In case of twins, both neonates will be included in the same treatment arm.
- Parental written informed consent for participation in the study obtained on admission into the hospital or prior to delivery.
- Evidence of severe birth asphyxia, that is an APGAR score below 3 at 5 minutes of age.
- Need for endotracheal intubation for cardiopulmonary resuscitation or insufficient respiratory drive.
- Known genetic or chromosomal disorders.
- Delivered to mothers with ruptured membranes of more than 3 weeks duration.
- Potentially life-threatening conditions unrelated to immaturity.
- Participation in another clinical trial of any placebo, drug, biological, or device conducted under the provisions of a protocol.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 2 Poractant alfa (Curosurf®) Poractant alfa (Curosurf) + N Cpap in delivery room
- Primary Outcome Measures
Name Time Method Need for MV Within the first 5 days of life
- Secondary Outcome Measures
Name Time Method Incidence of BPD and other complications of prematurity. Lenght of hospitalization. Clinical status until discharge home entire study
Trial Locations
- Locations (5)
Maternidade Alfredo da Costa
🇵🇹Lisbon, Portugal
Hospital De Cruces
🇪🇸Bilbao, Spain
General Faculty Hospital
🇨🇿Prague, Czechia
Ospedale Maggiore
🇮🇹Bologna, Italy
Hopital De La Conception
🇫🇷Marseille, France